-transparent.png){kind=logo}
Thrombocytopenia associated with gold therapy is thought to be due to an immune-mediated mechanism. Relatively few patients have been studied so far, and precise details of the pathophysiology of this disease remain undetermined. We report a patient with gold-induced thrombocytopenia resulting from auranofin therapy. The patient's plasma contained platelet-reactive antibodies detectable only in the presence of gold salts. Antibody binding occurred at gold concentrations ranging from 0.01 to 10,000 ng/ml. The binding occurred independently of gold salt used, suggesting that substitution of a different gold preparation in this patient would result in a similar thrombocytopenia. These data support a drug-dependent immune mechanism for platelet destruction.
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
February 1991,
British journal of rheumatology,
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
August 1975,
The American journal of medicine,
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
July 1986,
British journal of haematology,
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
October 2021,
Discover. Oncology,
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
August 1982,
Journal of the American Veterinary Medical Association,
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
January 1986,
Dermatologica,
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
December 1983,
The American journal of medicine,
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
September 1990,
Biochemical pharmacology,
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
November 1957,
Casopis lekaru ceskych,
M P Kosty, and
P K Hench, and
P Tani, and
R McMillan
July 1958,
Canadian Medical Association journal,
